Nexavar enters Phase III for breast cancer
This article was originally published in Scrip
Executive Summary
Bayer and Onyx Pharmaceuticals have taken their multitargeted anticancer agent Nexavar (sorafenib) into Phase III testing for another indication, advanced breast cancer.